TY - JOUR T1 - Effect of atorvastatin 1% mouthwash in the prevention of radiotherapy induced mucositis: A pilot study TT - JF - babol-caspjim JO - babol-caspjim VL - 13 IS - 4 UR - http://caspjim.com/article-1-2805-en.html Y1 - 2022 SP - 800 EP - 804 KW - Atorvastatin KW - Mouthwash KW - Oral mucositis KW - Radiotherapy N2 - Background: Oral mucositis is a troublesome symptom for people who receive radiotherapy and chemotherapy and it is a dose-dependent factor. Atorvastatin is a HMG-CoA reductase inhibitors and various studies have proven its anti-inflammatory effects. The goal of this study was to evaluate atorvastatin 1% mouthwash effects in prevention of radiotherapy-induced mucositis. Methods: Atorvastatin 1% suspension was prepared for mouthwash in this randomized, double-blind clinical trial. Thirty patients randomly received atorvastatin or placebo mouthwash. They had to gargle 5cc of mouthwash, 3 times per day during radiotherapy. The severity and pain of mucositis was evaluated every week, during their treatment. Results: The severity of mucositis between the two study groups was significant every four weeks (p<0.05) and the percentage of patients with more severe mucositis was less in the atorvastatin group. It is found that the pain intensity was lower after 3 and 4 weeks in atorvastatin group. Conclusion: These findings indicated that atorvastatin mouthwash showed a significant activity in relieving of radiotherapy-induced oral mucositis and pain. M3 10.22088/cjim.13.4.800 ER -